CAROTENOIDS, CHOLESTYRAMINE AND CORONARY HEART DISEASE

类胡萝卜素最近被认为可以预防冠心病 通过防止低密度脂蛋白氧化引起的疾病(CHD) 更易致动脉粥样硬化的化合物。拟议的研究将检验这一点。 通过检验冠心病血脂研究诊所的数据提出假说 一级预防试验(LRC-CPPT)和随访。这是随机的， 一项安慰剂对照试验检查了氯乙四胺在 降低高脂血症男性的冠心病。基线血清类胡萝卜素 测量和CHD事件/死亡可用于这一队列 3700名男性，14年随访。基线之间的关系 血清类胡萝卜素和随后的CHD将在安慰剂中进行检查 对吸烟和其他重要协变量进行了分组调整。这 关系也将在胆碱胺组中进行研究以评估 降脂与类胡萝卜素的相互作用 氯氰菊胺的作用。拟议的研究将增加重要的 关于使用类胡萝卜素预防 先心病。

Carotenoids have recently been postulated to prevent coronary heart disease (CHD) by the prevention of oxidation of low-density lipoproteins to more atherogenic compounds. The proposed study will test this hypothesis by examining data from the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) and Follow-up. This randomized, placebo-controlled trial examined the effectiveness of cholestyramine in reducing CHD among hyperlipidemic men. Baseline serum carotenoid measurements and CHD events/deaths are available for this cohort of over 3700 men with 14 year of follow-up. The relationship between baseline serum carotenoids and subsequent CHD will be examined in the placebo group adjusting for smoking and other important covariates. This relationship will also be studied in the cholestyramine group to assess the interaction between the lipid lowering and carotenoid lowering effects of cholestyramine. The proposed study will add important information concerning the possibility of using carotenoids to prevent CHD.